Yonsei Med J.  2014 May;55(3):834-837. 10.3349/ymj.2014.55.3.834.

Ibuprofen Associated Acute Vanishing Bile Duct Syndrome and Toxic Epidermal Necrolysis in an Infant

• Kim HY
• Yang HK
• Kim SH
• Park JH

• KMID: 2068699
• DOI: http://doi.org/10.3349/ymj.2014.55.3.834

Abstract

Acute vanishing bile duct syndrome, a rare but rapidly progressive destruction of the intrahepatic bile ducts with unknown pathogenesis, is most often a drug- or toxin-related. Toxic epidermal necrolysis is a serious dermatologic condition and a potentially life threatening disease, which is drug or infection induced. Ibuprofen associated acute vanishing bile duct syndrome and toxic epidermal necrolysis have not been reported previously in infants. We report a 7-month-old infant with ibuprofen associated toxic epidermal necrolysis, followed by severe and rapidly progressive vanishing bile duct syndrome. She recovered totally with supportive care.

Keyword

Acute vanishing bile duct syndrome; toxic epidermal necrolysis; infant

MeSH Terms

Female
Humans
Ibuprofen/*adverse effects
Infant
Stevens-Johnson Syndrome/*diagnosis/*etiology
Ibuprofen

Figure

• 

  Fig. 1 Liver histology shows portal lymphocytic infiltration with destruction of interlobular bile ducts (H&E, ×200) (A), (H&E, ×400) (B), intralobular canalicular cholestasis (H&E, ×200) (C), and absence of bile ducts demonstrated by cytokeratin 7 immunohistochemical staining (IHC, ×200) (D).

Reference

1. Srivastava M, Perez-Atayde A, Jonas MM. Drug-associated acute onset vanishing bile duct and Stevens-Johnson syndromes in a child. Gastroenterology. 1998; 115:743–746.

2. Taghian M, Tran TA, Bresson-Hadni S, Menget A, Felix S, Jacquemin E. Acute vanishing bile duct syndrome after ibuprofen therapy in a child. J Pediatr. 2004; 145:273–276.

3. Degott C, Feldmann G, Larrey D, Durand-Schneider AM, Grange D, Machayekhi JP, et al. Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology. 1992; 15:244–251.

4. Karnsakul W, Arkachaisri T, Atisook K, Wisuthsarewong W, Sattawatthamrong Y, Aanpreung P. Vanishing bile duct syndrome in a child with toxic epidermal necrolysis: an interplay of unbalanced immune regulatory mechanisms. Ann Hepatol. 2006; 5:116–119.

5. Okan G, Yaylaci S, Peker O, Kaymakoglu S, Saruc M. Vanishing bile duct and Stevens-Johnson syndrome associated with ciprofloxacin treated with tacrolimus. World J Gastroenterol. 2008; 14:4697–4700.

6. Morelli MS, O'Brien FX. Stevens-Johnson Syndrome and cholestatic hepatitis. Dig Dis Sci. 2001; 46:2385–2388.

7. Garcia M, Mhanna MJ, Chung-Park MJ, Davis PH, Srivastava MD. Efficacy of early immunosuppressive therapy in a child with carbamazepine-associated vanishing bile duct and Stevens-Johnson syndromes. Dig Dis Sci. 2002; 47:177–182.

8. Stine JG, Lewis JH. Drug-induced liver injury: a summary of recent advances. Expert Opin Drug Metab Toxicol. 2011; 7:875–890.

9. Sternlieb P, Robinson RM. Stevens-Johnson syndrome plus toxic hepatitis due to ibuprofen. N Y State J Med. 1978; 78:1239–1243.

10. Alam I, Ferrell LD, Bass NM. Vanishing bile duct syndrome temporally associated with ibuprofen use. Am J Gastroenterol. 1996; 91:1626–1630.

11. Takeyama J, Saito T, Itagaki T, Abukawa D. Vanishing bile duct syndrome with a history of erythema multiforme. Pediatr Int. 2006; 48:651–653.

12. Tajiri H, Etani Y, Mushiake S, Ozono K, Nakayama M. A favorable response to steroid therapy in a child with drug-associated acute vanishing bile duct syndrome and skin disorder. J Paediatr Child Health. 2008; 44:234–236.